The development marks a shift up the value chain for labs and could prove a meaningful revenue stream for providers able to ...

Through clinical trials, partnerships, and economic studies, a crop of test developers is trying to prove the value of their ...

The Uppsala University spinout aims to use its SuperRCA mutation detection technology for applications including molecular residual disease monitoring.

The test, which Santa Maria, California-based Hardy distributes in the US under a license from NG Biotech, is designed to detect CTX-M enzymes.

Some experts believe a technological tipping point is imminent, if not already here, but adoption of point-of-care MDx has ...

The company reported difficulties ahead for its immunodiagnostics business in China in the wake of changes in late April related to the country's Diagnosis-Related Groups (DRG) policy on hospital lab ...

Last week, readers were most interested in a story about Roche's blood-based Alzheimer's test getting CE marking.

The deal brings together Promega's Maxwell automated nucleic acid extraction system and Longhorn's viral molecular transport media.

The company raised its full-year revenue guidance slightly due to changing foreign exchange rates but lowered its full-year EPS guidance.

An assessment of the documentation for 30 over-the-counter diagnostic tests found none met the current regulatory standards.

The blood test is designed to detect the accumulation of amyloid protein deposits in the brain, a hallmark of Alzheimer's disease.

The firm saw growth in its core laboratory segment but declines in molecular, point of care, and rapid diagnostics.